1.
Obesity, inflammation, and atherosclerosis
by Libby, Peter
Nature reviews cardiology, 2009, Vol.6 (6), p.399-409
2.
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
by DeFronzo, R. A
Diabetologia, 2010, Vol.53 (7), p.1270-1287
3.
Immune and inflammatory mechanisms of atherosclerosis ()
by Galkina, Elena
Annual review of immunology, 2009, Vol.27 (1), p.165-197
4.
Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease
by Gray, Stephen P
Diabetologia, 2017, Vol.60 (5), p.927-937
5.
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
by Makowski, Liza
Nature, 2007, Vol.447 (7147), p.959-965
6.
Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice
by Gomez, Delphine
Nature medicine, 2018, Vol.24 (9), p.1418-1429
7.
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet
by Han, Ji Hye
Diabetologia, 2016, Vol.60 (2), p.364-376
8.
Inflammation and immune system interactions in atherosclerosis
by Legein, Bart
Cellular and molecular life sciences : CMLS, 2013, Vol.70 (20), p.3847-3869
9.
Translating molecular discoveries into new therapies for atherosclerosis
by Rader, Daniel J
Nature, 2008, Vol.451 (7181), p.904-913
10.
MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion
by Soh, James
Nature medicine, 2013, Vol.19 (7), p.892-900
11.
Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – Novel insights and future directions in diagnosis and therapy
by Hartley, Adam
Trends in cardiovascular medicine, 2019, Vol.29 (1), p.22-26
12.
Ameliorating Endothelial Mitochondrial Dysfunction Restores Coronary Function via Transient Receptor Potential Vanilloid 1-Mediated Protein Kinase A/Uncoupling Protein 2 Pathway
by Xiong, Shiqiang
Hypertension (Dallas, Tex. 1979), 2016, Vol.67 (2), p.451-460
13.
LOX-1 in atherosclerosis: biological functions and pharmacological modifiers
by Xu, Suowen
Cellular and molecular life sciences : CMLS, 2013, Vol.70 (16), p.2859-2872
14.
Metabolomic Profile Associated With Insulin Resistance and Conversion to Diabetes in the Insulin Resistance Atherosclerosis Study
by Palmer, Nicholette D
The journal of clinical endocrinology and metabolism, 2015, Vol.100 (3), p.E463-E468
15.
Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?
by Kralisch, S
Diabetologia, 2012, Vol.56 (1), p.10-21
16.
Oxidized LDL: Diversity, Patterns of Recognition, and Pathophysiology
by Levitan, Irena
Antioxidants & redox signaling, 2010, Vol.13 (1), p.39-75
17.
The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?
by Rader, Daniel J
Nature medicine, 2012, Vol.18 (9), p.1344-1346
18.
Role of cholesterol and lipid organization in disease
by Maxfield, Frederick R
Nature, 2005, Vol.438 (7068), p.612-621
19.
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
by Panjwani, Naim
Endocrinology (Philadelphia), 2013, Vol.154 (1), p.127-139
20.
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice
by Weber, Christian
Nature medicine, 2009, Vol.15 (1), p.97-103
